The Filing Desk

Guardant Health

GH · Nasdaq · Health Care · Financials, fiscal 2016 to 2025

GH · Last close · November 19, 2026
$145.59
Value Guardant Health yourself

Guardant Health's revenue rose 32.9% to $982 million in fiscal 2025. Its operating margin was −44.5%, up from −60.0% a year earlier. Free cash flow was −$233 million. It paid out $45 million in dividends and buybacks. The diluted share count rose 2.1%.

GUARDANT HEALTH, INC. Latest fiscal year ended December 31, 2025 10-K filed February 19, 2026 · 0001576280-26-000013 Updated
Revenue
$982M
32.9%
Operating margin
−44.5%
15.5 pts
Net income
−$416M
 
Free cash flow
−$233M
 
Return on capital
−188.8%
 
Market cap
$19.6B
Nov 19 close
P/E
—
Loss: no P/E

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

Charts show fiscal years, from the 10-K filings.

What Guardant Health does

Guardant Health makes blood and tissue tests for cancer, run in its own laboratories. For patients with advanced cancer, its Guardant360 tests look for gene changes in a tumor to help doctors choose a treatment. Its Guardant Reveal test watches for cancer coming back after treatment. Its Shield blood test screens adults 45 and older for colorectal cancer, and the 10-K says it was the first blood test the FDA approved for that purpose.

The company had total revenue of $982.0 million in 2025, and it still lost money. Oncology tests for doctors and hospitals brought in $683.6 million. Work for drug makers, who use its tests and data in clinical trials, brought in $210.1 million. Shield screening brought in $79.7 million. It names Foundation Medicine among its competitors in tests used to choose a therapy.

At the end of 2025 Guardant had 2,506 employees, most of them in the United States. Medicare paid for more than a tenth of its revenue in each of the past three years.

Its biggest risks, as it describes them

  • It has lost money since it began and may not earn enough revenue to become profitable.
  • Insurers and Medicare may not cover its tests or pay enough for them.
  • Stricter FDA rules for lab-developed tests could add costly requirements for several of its tests.
  • Rivals entering liquid biopsy and cancer screening could slow the adoption of its tests.
  • Its reliance on a few suppliers, couriers and its main laboratory to process samples.
From Guardant Health's annual report on Form 10-K, filed February 19, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

Guardant Health lost money in fiscal 2025: a net loss of $416 million.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments9331,0111,1698401,202
Debt incl. finance leases1,1351,1371,1401,1421,504
Net debt (negative means net cash)202126−29302302
Net debt to EBITDA—————
Debt to equity1.8x—7.2x——
Interest coverage−159.5x−211.2x−219.1x−171.9x−112.2x
Current ratio5.7x6.2x6.5x4.7x4.8x
Quick ratio5.6x5.9x6.2x4.4x4.6x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project Guardant Health's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

What Guardant Health says to expect

  • Full year 2026: revenueGuardant Health now expects full year 2026 revenue to be in the range of $1.36 to $1.37 billion, representing growth of 38% to 40% compared to full year 2025.
  • Full year 2026: screening revenue and Shield volumeScreening revenue is now expected to be in the range of $233 to $238 million, driven by Shield volume of 285,000 to 290,000 tests.
  • Full year 2026: non-GAAP gross marginGuardant Health now expects full year 2026 non-GAAP gross margin to be 65%, compared to prior guidance of 64% to 65%.
The company's own words, from its earnings release (Form 8-K, Exhibit 99), filed November 5, 2026. They are its expectations, not ours, and not a forecast or price target from The Filing Desk. Replaced when the next release is out.

Insider trades

Over the 12 months between November 20, 2025 and November 19, 2026, 1 insider bought $78,456 of Guardant Health shares on the open market, and 15 insiders sold $173.5 million, $81.7 million of it under trading plans set up in advance.

Buys and sells by month
US$ millions, open-market purchases (up) and sales (down) by officers, directors and 10% owners in each month.
BoughtSold
DateInsiderTradeSharesPriceValueFiling
Nov 18, 2026Terilyn J. MonroeChief People OfficerSold plan3,842$142.41$547,149Form 4
Nov 16, 2026Musa TariqDirectorSold plan116$149.56$17,349Form 4
Nov 16, 2026Alex M Azar IIDirectorSold plan69$149.56$10,320Form 4
Sep 16, 2026Steve E. KrognesDirectorSold6,674$175.74$1.2 millionForm 4
Sep 16, 2026Alex M Azar IIDirectorSold plan826$175.00$144,550Form 4
Sep 16, 2026Musa TariqDirectorSold plan116$175.00$20,300Form 4
Sep 15, 2026Darya ChudovaChief Technology OfficerSold7,738$178.00$1.4 millionForm 4
Sep 11, 2026Kumud KaliaChief Information OfficerSold4,000$158.05$632,200Form 4
Aug 21, 2026AmirAli TalasazCo-Chief Executive Officer, DirectorSold37,500$169.16$6.3 millionForm 4
Aug 17, 2026Musa TariqDirectorSold plan116$156.45$18,148Form 4
Aug 12, 2026Terilyn J. MonroeChief People OfficerSold46,300$165.12$7.6 millionForm 4
Aug 10, 2026Chris FreemanChief Commercial OfficerSold63,605$169.58$10.8 millionForm 4
The latest 12 of 57 trades. Open-market purchases and sales by officers, directors and 10% owners, from their Form 4 filings with the SEC: one row per person, day and filing, at the day's average price. Grants, option exercises and shares withheld for tax aren't counted. Insiders buy and sell for many reasons, such as taxes, spreading their savings or a plan set up months earlier, so a trade on its own says little about where a company is heading. For information only, not investment advice. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score3 of 84 of 94 of 9
Rule of 40−35.8%−6.2%9.2%
Altman Z''−1.74−4.09−2.57
Accruals ratio−9.1%−12.0%−13.2%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positiveFailFailFail
Cash from operations is positiveFailFailFail
Return on assets roseFailPassFail
Cash from operations exceeds net incomePassPassPass
Debt fell relative to assetsFailFailFail
Current ratio rosePassFailPass
Share count didn't riseFailFailFail
Gross margin rose—PassPass
Revenue rose relative to assetsPassPassPass
F-score3 of 84 of 94 of 9
Companies that report no gross profit are scored on the other eight.

Compare

Put Guardant Health side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
Guardant HealthFY2532.9%−44.5%−23.7%−188.8%—4
InnovAgeFY2615.9%0.3%5.1%0.7%−3.3x6Compare
CorVelFY267.0%—11.5%———Compare
Pennant GroupFY2536.3%5.5%3.8%9.3%2.6x5Compare
Sotera HealthFY255.7%—12.8%6.7%—7Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

10 years of figures

Fiscal yearFY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue255091214287374450564739982
Revenue growth—97.4%81.8%136.5%33.8%30.3%20.3%25.4%31.0%32.9%
Gross profit———————337449633
Research and development11265186150263374367348364
Operating income−44−77−93−82−255−411−544−565−444−437
Net income−46−83−85−76−246−385−655−479−436−416
Diluted EPS (US$)−3.53−7.07−2.80−0.84−2.60−4.00−6.41−4.28−3.56−3.32
Diluted shares (millions)1313309198101102112123125
Cash flow
Cash from operations−37−72−72−47−104−209−310−325−240−185
Capital expenditure272019367578203548
Free cash flow−38−79−92−66−140−284−387−345−275−233
Dividends paid0000000000
Share buybacks07000000045
Acquisitions00070000059
Stock-based compensation247171441519591140166
Balance sheet at fiscal year end
Cash and short-term investments342214195231,7959331,0111,1698401,202
Debt incl. finance leases———08061,1351,1371,1401,1421,504
Total assets—3435879622,2722,2041,6101,7861,4862,014
Total liabilities—34621149161,5601,5501,6281,6252,113
Shareholders' equity803094837981,29864560159−140−99
Margins and ratios
Gross margin———————59.7%60.8%64.5%
Operating margin−173.7%−153.7%−102.5%−38.4%−88.9%−110.0%−121.1%−100.1%−60.0%−44.5%
Net margin−182.7%−167.0%−93.8%−35.3%−85.9%−103.0%−145.6%−85.0%−59.0%−42.4%
Free cash flow margin−152.4%−158.3%−101.9%−30.7%−48.9%−76.0%−86.1%−61.3%−37.2%−23.7%
Rule of 40 (growth + FCF margin)—−60.9%−20.1%105.8%−15.1%−45.7%−65.8%−35.8%−6.2%9.2%
Return on capital————−68.8%−56.1%−83.2%——−188.8%
Return on equity——−21.5%−11.8%−23.5%−39.6%−185.7%−438.1%——
Return on assets——−18.3%−9.8%−15.2%−17.2%−34.3%−28.2%−26.7%−23.8%
Net debt to EBITDA——————————
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: Guardant Health's Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with Guardant Health.